Dr. Aaric John Allred, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 225 E Main St, Suite G, Grantsville, UT 84029 Phone: 435-884-3088 |
Dr. Benjamin Alexander Cluff, D.D.S Dentist Medicare: Not Enrolled in Medicare Practice Location: 14 N Hale St, Grantsville, UT 84029 Phone: 435-884-3476 Fax: 435-884-6790 |
Mr. Robert Stanley Albiston, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 14 N. Hale Street, Grantsville, UT 84029 Phone: 435-884-3476 Fax: 435-884-6790 |
Dr. Shane M Juber, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 14 N Hale St, Grantsville, UT 84029 Phone: 435-884-3002 |
News Archive
iMedicor (VMCI.OB) formerly Vemics, Inc. and EP Global Communications (EPGL.OB) have announced the renewal of their strategic alliance agreement to produce Continuing Medical Education (CME) and non-accredited education programs for people with special needs and life long chronic disabilities. iMedicor/Vemics and EP Global Communications have worked together for a number of years and this relationship has generated substantial revenue for both companies and has provided a valuable service to the community they serve.
GlaxoSmithKline and Medivir today announced an exclusive agreement for the commercialization of cold sore treatment, Xerclear (acyclovir and hydrocortisone) for non-prescription use (OTC) in key global markets. Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.
Genzyme Corporation announced today that the FDA notified the company yesterday afternoon that, while the agency recognizes Genzyme's efforts, it intends to take enforcement action to ensure that products manufactured at the plant are made in compliance with good manufacturing practice regulations. The FDA enforcement action will likely result in a consent decree, under which a third party would inspect and review the plant's operation for an extended period and certify compliance with FDA regulations.
› Verified 5 days ago